Cidara Therapeutics, Inc. (CDTX)
- Previous Close
0.6810 - Open
0.5900 - Bid 0.4790 x 100
- Ask 0.5486 x 100
- Day's Range
0.5002 - 0.6480 - 52 Week Range
0.5002 - 1.4800 - Volume
3,702,218 - Avg. Volume
758,115 - Market Cap (intraday)
46.569M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-0.3900 - Earnings Date Apr 23, 2024 - Apr 24, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
5.60
Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and the SARS-CoV-2 strains causing COVID-19. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.
www.cidara.comRecent News: CDTX
Performance Overview: CDTX
Trailing total returns as of 4/22/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CDTX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CDTX
Valuation Measures
Market Cap
46.58M
Enterprise Value
2.27M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.75
Price/Book (mrq)
5.79
Enterprise Value/Revenue
0.04
Enterprise Value/EBITDA
-0.07
Financial Highlights
Profitability and Income Statement
Profit Margin
-35.88%
Return on Assets (ttm)
-26.70%
Return on Equity (ttm)
--
Revenue (ttm)
63.91M
Net Income Avi to Common (ttm)
-22.93M
Diluted EPS (ttm)
-0.3900
Balance Sheet and Cash Flow
Total Cash (mrq)
35.78M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
9.14M